Clozapine concentration and adverse reactions: Impact of smoking
The Brown University Psychopharmacology Update · 2026-03 · 37 (3) · 2-2
DOI: 10.1002/pu.31416 ↗Kurz gefasst
Fachartikel in der Zeitschrift The Brown University Psychopharmacology Update, online erschienen am 23.02.2026. Verfasst von Y. W. Francis Lam. Die Arbeit nennt 2 Literaturangaben.
Abstract (Originalsprache)
The atypical antipsychotic clozapine is uniquely efficacious in addressing treatment‐resistant schizophrenia. There are significant variations, however, in its pharmacokinetic profile among treated patients, resulting from altered metabolic capacity secondary to drug‐drug interaction and/or smoking status (Haring et al., 1989). Smoking cigarettes produces chemicals that act as potent inducers of the activity of CYP1A2, the primary enzyme responsible for the metabolism of clozapine to the active metabolite norclozapine.
Zitieren
APA
Lam, Y. W. F. (2026). Clozapine concentration and adverse reactions: Impact of smoking. The Brown University Psychopharmacology Update, 37(3), 2-2. https://doi.org/10.1002/pu.31416
Vancouver
Lam YWF. Clozapine concentration and adverse reactions: Impact of smoking. The Brown University Psychopharmacology Update. 2026;37(3):2-2. doi:10.1002/pu.31416
BibTeX
@article{Lam2026,
author = {Lam, Y. W. Francis},
title = {Clozapine concentration and adverse reactions: Impact of smoking},
journal = {The Brown University Psychopharmacology Update},
year = {2026},
volume = {37},
number = {3},
pages = {2--2},
doi = {10.1002/pu.31416}
}
EUVIMED